Who are CCRT with weekly docetaxel & cisplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taxanes plus Carboplatin, Vincristin , Adriamycin, Dexamethasone = VAD, docetaxel - cisplatin - 5-fluorouracil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ccrt-with-weekly-docetaxel-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CCRT with weekly docetaxel & cisplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CCRT with weekly docetaxel & cisplatin (CCRT with weekly docetaxel & cisplatin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane and platinum-based chemotherapeutic agents. Area: Oncology.

phase 2 Taxane and platinum-based chemotherapeutic agents Microtubules and DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CCRT with weekly docetaxel & cisplatin (CCRT with weekly docetaxel & cisplatin) — Samsung Medical Center. Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CCRT with weekly docetaxel & cisplatin TARGET	CCRT with weekly docetaxel & cisplatin	Samsung Medical Center	phase 2	Taxane and platinum-based chemotherapeutic agents	Microtubules and DNA
Taxanes plus Carboplatin	Taxanes plus Carboplatin	Shanghai Jiao Tong University School of Medicine	phase 3	Taxane and platinum-based chemotherapeutic agent	Microtubules and DNA
Vincristin , Adriamycin, Dexamethasone = VAD	Vincristin , Adriamycin, Dexamethasone = VAD	University Hospital, Caen	phase 3	Vinca alkaloid and anthracycline antibiotic	Microtubules and DNA
docetaxel - cisplatin - 5-fluorouracil	docetaxel - cisplatin - 5-fluorouracil	Gruppo Oncologico del Nord-Ovest	phase 3	Taxane and platinum-based chemotherapy	Microtubules and DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane and platinum-based chemotherapeutic agents class)

Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CCRT with weekly docetaxel & cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/ccrt-with-weekly-docetaxel-cisplatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab